Navigation Links
Cynosure Appoints H. Travis Lee as Vice President of Global Marketing

WESTFORD, Mass., May 14 /PRNewswire-FirstCall/ -- Cynosure, Inc. (Nasdaq: CYNO), a leading developer and manufacturer of a broad array of light-based aesthetic treatment systems, today announced the appointment of H. Travis Lee as vice president of global marketing. Lee will develop and implement worldwide strategic marketing initiatives for all of Cynosure's flagship products, including the Smartlipo MPX, the company's newest system for laser lipolysis, which will debut internationally in the second half of this year.

"As a global marketing executive, Travis has produced outstanding results in a career that spans more than two decades and includes two of the medical device industry's leading companies -- Smith & Nephew and Boston Scientific," said Cynosure President and Chief Executive Officer Michael Davin. "Colleagues and co-workers praise his ability to articulate brand value, cultivate strong relationships with key opinion leaders and identify new business opportunities."

Lee joined Cynosure from the global medical technology company Smith & Nephew Inc., where he served as global director of marketing for the endoscopy division, with responsibility for two franchises that accounted for more than $300 million in revenue. In addition to building and leading the department, he developed key opinion leaders and integrated them into the division's product development process, and led the efforts behind two significant acquisition targets.

Prior to that he worked for more than five years at Boston Scientific Corp., a manufacturer of products for minimally invasive surgical procedures, first as principal product manager in the urology/gynecology division and then as group product manager in the neurovascular division. In this role he had global responsibility for a product line with 70% worldwide market share.

In addition, Lee has worked in executive marketing positions for companies including Cell Robotics, Inc., Medasonics, Inc., Xintec Corp. and Heraeus Surgical Inc., which was later acquired by Laserscope. Among his accomplishments at Heraeus Surgical, Lee managed the investigation, implementation and launch of a new CO2 laser system for cosmetic applications that generated more than $10 million in sales in less than six months. He also successfully launched four new capital laser equipment products and more than 10 new disposable and reusable laser accessories in his first year.

"Cynosure has built an international reputation for technology innovation and product excellence," Lee said. "With the international launch of the Smartlipo MPX scheduled for the second half of this year, this is a particularly exciting time to join the company. I look forward to leading the marketing team as we focus on continuing the success that has established Cynosure as the fastest-growing company in the aesthetic industry."

About Cynosure, Inc.

Cynosure, Inc. develops and markets aesthetic treatment systems that are used by physicians and other practitioners to perform non-invasive and minimally invasive procedures to remove hair, treat vascular lesions, rejuvenate skin through the treatment of shallow vascular and pigmented lesions, laser lipolysis and temporarily reduce the appearance of cellulite. Cynosure's products include a broad range of laser and other light-based energy sources, including Alexandrite, pulsed dye, Nd:YAG and diode lasers, as well as intense pulsed light. Cynosure was founded in 1991. For corporate or product information, contact Cynosure at 800-886-2966, or visit

Safe Harbor

Any statements in this press release about future expectations, plans and prospects for Cynosure, Inc., including statements about the company's expectations and future financial performance, as well as other statements containing the words "believes," "anticipates," "plans," "expects," "will" and similar expressions, constitute forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including Cynosure's reliance on sole source suppliers, the inability to accurately predict the timing or outcome of regulatory decisions, changes in consumer preferences, competition in the aesthetic laser industry, economic, market, technological and other factors discussed in Cynosure's most recent Annual Report on Form 10-K, which is filed with the Securities and Exchange Commission. In addition, the forward-looking statements included in this press release represent Cynosure's views as of the date of this press release. Cynosure anticipates that subsequent events and developments will cause its views to change. However, while Cynosure may elect to update these forward-looking statements at some point in the future, it specifically disclaims any obligation to do so. These forward-looking statements should not be relied upon as representing Cynosure's views as of any date subsequent to the date of this press release.

SOURCE Cynosure, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Cynosure Reports 41% Revenue Increase: 10th Consecutive Quarter of Revenue Growth
2. Cynosure Introduces Smartlipo MPX(TM) Dual Wavelength Workstation for LaserBodySculpting(SM)
3. Cynosure Announces Upcoming Investor Presentations at Cowen and Citi Investor Conferences
4. Cynosure Reports Record Revenues and Net Income for the Fourth Quarter of 2007
5. Cynosure to Announce Fourth-Quarter and Full Year 2007 Financial Results on February 12
6. Cynosure to Present at the Leerink Swann & Company/MEDACorp Aesthetics Roundtable Conference
7. Biopure Appoints Dechra Exclusive U.S. Distributor of Oxyglobin
8. Angiotech appoints Hank McKinnell to its Board of Directors
9. Adnavance Technologies Inc. Appoints Christian P. Valcke, Ph.D., to Its Scientific Advisory Board
10. Verenium Appoints John F. Dee to Board of Directors
11. Cytochroma Appoints R. Richard Wieland II As CFO
Post Your Comments:
(Date:11/25/2015)... SAN DIEGO , Nov. 25, 2015 ... that management will participate in a fireside chat discussion ... New York . The discussion is ... Time. .  A replay will ... Contact:  Media Contact:McDavid Stilwell  , Julie NormartVP, Corporate ...
(Date:11/25/2015)... ... November 25, 2015 , ... Jessica Richman and ... early in their initial angel funding process. Now, they are paying it forward ... make early stage investments in the microbiome space. In this, they join ...
(Date:11/24/2015)... ... November 24, 2015 , ... The United States Golf ... the 2016 USGA Green Section Award. Presented annually since 1961, the USGA Green Section ... her work with turfgrass. , Clarke, of Iselin, N.J., is an extension ...
(Date:11/24/2015)... 2015 Halozyme Therapeutics, Inc. (NASDAQ: HALO ) will ... New York on Wednesday, December 2 at 9:30 a.m. ... and CEO, will provide a corporate overview. th ... at 1:00 p.m. ET/10:00 a.m. PT . Jim Mazzola ... a corporate overview. --> th Annual Oppenheimer Healthcare ...
Breaking Biology Technology:
(Date:11/12/2015)... 2015  Arxspan has entered into an agreement ... for use of its ArxLab cloud-based suite of ... partnership will support the institute,s efforts to electronically ... information internally and with external collaborators. The ArxLab ... the Institute,s electronic laboratory notebook, compound and assay ...
(Date:11/11/2015)... , Nov. 11, 2015   MedNet Solutions , ... spectrum of clinical research, is pleased to announce that it ... Clinical Trials (PCT) event, to be held November 17-19 ... able to view live demonstrations of iMedNet ... learn how iMedNet has been able to deliver ...
(Date:11/10/2015)... 2015 About signature verification ... to identify and verify the identity of an ... the secure and accurate method of authentication and ... individual because each individual,s signature is highly unique. ... dynamic signature of an individual is compared and ...
Breaking Biology News(10 mins):